Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms
Context Lower urinary tract symptoms (LUTS) are common, often bothersome, and have
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management
Purpose: Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction
M Oelke, A Bachmann, A Descazeaud, M Emberton… - European urology, 2013 - Elsevier
OBJECTIVE: To present a summary of the 2013 version of the European Association of
Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms …
Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms …
Benign prostatic hyperplasia
RC Langan - Primary Care: Clinics in Office Practice, 2019 - primarycare.theclinics.com
Benign prostatic hyperplasia (BPH) is the most common benign neoplasm of aging men and
is present in approximately 8% of men in the fourth decade of life but up to 90% of men in …
is present in approximately 8% of men in the fourth decade of life but up to 90% of men in …
Management of benign prostatic hyperplasia
EH Kim, JA Larson, GL Andriole - Annual review of medicine, 2016 - annualreviews.org
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS)
commonly affect older men. Age-related changes associated with metabolic disturbances …
commonly affect older men. Age-related changes associated with metabolic disturbances …
Prevention of prostate cancer morbidity and mortality: primary prevention and early detection
MJ Barry, LH Simmons - Medical Clinics, 2017 - medical.theclinics.com
Disclosure: Dr MJ Barry is President of the Informed Medical Decisions Foundation, a part of
Healthwise, where he is also Chief Science Officer. Healthwise is a 501 (c) 3 nonprofit …
Healthwise, where he is also Chief Science Officer. Healthwise is a 501 (c) 3 nonprofit …
The 5 alpha‐reductase isozyme family: a review of basic biology and their role in human diseases
F Azzouni, A Godoy, Y Li, J Mohler - Advances in urology, 2012 - Wiley Online Library
Despite the discovery of 5 alpha‐reduction as an enzymatic step in steroid metabolism in
1951, and the discovery that dihydrotestosterone is more potent than testosterone in 1968 …
1951, and the discovery that dihydrotestosterone is more potent than testosterone in 1968 …
Benign prostatic hyperplasia and lower urinary tract symptoms
AV Sarma, JT Wei - New England Journal of Medicine, 2012 - Mass Medical Soc
Key Clinical Points Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms Lower
urinary tract symptoms—including obstructive symptoms (eg, urinary hesitancy and weak …
urinary tract symptoms—including obstructive symptoms (eg, urinary hesitancy and weak …
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta‐analysis
M Gacci, V Ficarra, A Sebastianelli… - The journal of sexual …, 2014 - academic.oup.com
Introduction Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due
to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side …
to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side …
Association of suicidality and depression with 5α-reductase inhibitors
Importance There have been concerns raised by patients and regulatory agencies regarding
serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective To …
serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective To …